and has multiple subsidiaries which “provides SAP cloud, digital and enterprise services worldwide.” They have established relationships with IT Companies like Google Cloud, SAP Partner, Inpedic, and The Glimpse Group, to name a few, and have global delivery centers in India.

— Billy (@StonkDomBilly) July 21, 2020

Since then the stock price has began to level out close to that $2 mark. Now lets dive into Jay Pharma. Jay Pharma (JP) is a Canadian company dedicated to developing innovative, evidence-based cannabinoid products and combination therapies to address unmet needs in cancer care.

— Billy (@StonkDomBilly) July 21, 2020

On June 2nd, JP was granted IBA approval for testing proprietary CBD Formulation in a rare form of aggressive brain cancer called Glioblastoma Multiforme (GBM) with the ultimate goal being to deliver FDA-approved combination therapies to cancer patients.

— Billy (@StonkDomBilly) July 21, 2020

Tikun Olam has 3 main proprietary strains, one of which "Avidekel" has been licensed to JP, and is specifically high in CBD and low in THC.

— Billy (@StonkDomBilly) July 21, 2020

JP is also already preparing for the merger (sounds like they expect this to be voted through with ease) as they announced in their 2020 shareholder letter that they will be bringing on former CIA Director Jim Woolsey who “has been actively involved in working with…

— Billy (@StonkDomBilly) July 21, 2020

Lastly, aside from the relatively low volume as buyers have trickled out due to the recent offering, this chart is looking to make a big move upwards IMO. The finalization of the merger could be the push that sends this stock up quickly.

— Billy (@StonkDomBilly) July 21, 2020

https://twitter.com/StonkDomBilly/status/1285397262538072065

⬇ ⬇ ⬇ What do you think of this DD? Leave a rating below!